A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Trial Profile

A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Graft-versus-host disease
  • Focus Adverse reactions
  • Acronyms DOTTI
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 18 Jan 2018 Status changed from recruiting to discontinued.
    • 14 May 2015 Data published in a Bellicum Pharmaceuticals media release.
    • 14 May 2015 According to a Bellicum Pharmaceuticals media release, data from this study were published in Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top